医院感染多重耐药鲍曼不动杆菌临床特征及耐药性分析

目的：分析医院感染多重耐药鲍曼不动杆菌临床特征及耐药情况，为临床合理使用抗菌药物提供依据。方法分离的358株鲍曼不动杆菌采用法国生物梅里埃公司ATB自动细菌鉴定分析系统进行细菌鉴定，K-B纸片扩散法进行药敏试验，对所得数据用WHONET5．4软件进行分析。结果临床分离出鲍曼不动杆菌358株，91．62％分离自痰与咽拭子的标本，52．23％来自重症监护病房（ ICU）；多重耐药鲍曼不动杆菌217株占总数的60．61％。多重耐药鲍曼不动杆菌对多黏菌素B耐药率最低（0．0％），其次为米诺环素（5.1％）、头孢哌酮/舒巴坦（9．8％）、奈替米星（21．1％）和美洛培南（41．5％）。结论 ICU病区的多重耐药鲍曼不动杆菌的比例明显高于其他病区，应根据药敏结果合理使用抗菌药物，减少和控制医院感染的发生。

Clinical feature and drug resistance of multi-drug resistant Acinetobacter baumanii in hospital

Objective To investigate the clinical feature of Acinetobacter baumannii and to provide the basis for clinical rational use of anti-microbial agents.Methods ATB system was used to identify Acinetobacter baumanii, and antimicrobial resistance was determined by Kirby-Bauer method.The results were analyzed by Whonet 5.4 soft-ware.Results A total of the 358 strains Acinetobacter baumannii were isolated,91.62% were from sputum and throat swab.The main departments was ICU（52.23%）;In 358 strains Acinetobacter baumannii,217 strains were multi-drug resistant strains（60.61%）.The drug resistance to polymyxin B was the lowest 0% followed by minocy-cline 19.8% and cefoperazone/sulbactam 9.8%, the next was netilmicin 21.1% and meropenem 41.5%. Conclusion Acinetobacter baumannii shows multi-drug resistance, especially in ICU.Anti-microbial agents should be the rational use according to the results of drug susceptibility in order to reduce and control the incidence of noso-comial infections.